Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Owen

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Cancers|June 28, 2023
Spontaneous EBV-Reactivation during B Cell Differentiation as a Model for Polymorphic EBV-Driven LymphoproliferationMatthew A Care, Sophie Stephenson, Roger Owen, et al.
Chest|February 26, 2011
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled studyKenneth R Chapman, Stephen I Rennard, Angeli Dogra, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2010
Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapySusan Martin, Mark Sydenham, Joanne Haviland, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 7, 2008
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthmaDavid S Pearlman, Leon Greos, Craig LaForce, et al.
Respiratory Research|October 6, 2010
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumClaus Vogelmeier, David Ramos-Barbon, Damon Jack, et al.
BMC Pulmonary Medicine|March 10, 2010
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyGregory Feldman, Thomas Siler, Niyati Prasad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximabSharon Barrans, Simon Crouch, Alex Smith, et al.
Current Medical Research and Opinion|February 6, 2009
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterolOlivier Bauwens, Vincent Ninane, Boudewijn Van de Maele, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2008
Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety studyWilliam H Yang, Jean Benoit Martinot, Petr Pohunek, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 10, 2005
Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trialJohn Yarnold, Anita Ashton, Judith Bliss, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Cancers|June 28, 2023
Spontaneous EBV-Reactivation during B Cell Differentiation as a Model for Polymorphic EBV-Driven LymphoproliferationMatthew A Care, Sophie Stephenson, Roger Owen, et al.
Chest|February 26, 2011
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled studyKenneth R Chapman, Stephen I Rennard, Angeli Dogra, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2010
Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapySusan Martin, Mark Sydenham, Joanne Haviland, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 7, 2008
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthmaDavid S Pearlman, Leon Greos, Craig LaForce, et al.
Respiratory Research|October 6, 2010
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumClaus Vogelmeier, David Ramos-Barbon, Damon Jack, et al.
BMC Pulmonary Medicine|March 10, 2010
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyGregory Feldman, Thomas Siler, Niyati Prasad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximabSharon Barrans, Simon Crouch, Alex Smith, et al.
Current Medical Research and Opinion|February 6, 2009
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterolOlivier Bauwens, Vincent Ninane, Boudewijn Van de Maele, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2008
Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety studyWilliam H Yang, Jean Benoit Martinot, Petr Pohunek, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 10, 2005
Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trialJohn Yarnold, Anita Ashton, Judith Bliss, et al.
Pageof 8